Clinical Trials Logo

Clinical Trial Summary

The vast majority of primary liver cancer (90%) is hepatocellular carcinoma (HCC), and the majority of HCC patients have been locally advanced or metastatic disease when they are diagnosed in clinics. Most of them are not suitable for radical treatment. In the case of supportive treatment, the median survival time was only 7.9 months. Therefore, there is an urgent need for effective treatment for these patients.

At present, the overall objective response rate (ORR) of single or sequential therapy is not satisfied, and the over survival (OS) improvement is not ideal. Therefore, combined therapy maybe the good choice for patients with advanced HCC.

This study focuses on the in-operable, middle and late stage (BCLC-B and BCLC-C) HCC patients. Through the combination of immunotherapy (PD-1 monoclonal antibody), local therapy (TACE) and anti-angiogenic therapy (lenvatinib), it is expected to change the tumor microenvironment, restore the immune response, strengthen the anti-tumor effect of various treatments, and improve the therapeutic efficacy in patients with middle and late stage HCC.


Clinical Trial Description

This study is a single arm, single center, non randomized, open label study. It is estimated that 56 patients with advanced HCC who can not receive radical resection will be enrolled.

The trial period of subjects includes screening period, treatment period and follow-up period.

The drug treatment was 240 mg of PD-1 monoclonal antibody, intravenous infusion on the first day, every 21 days as a treatment cycle; lenvatinib mesylate capsule, 12 mg (body weight ≥ 60 kg) or 8 mg (body weight < 60 kg), oral once a day, continuous oral; TACE, the blank microspheres and lobaplatin (30 mg) + epirubicin (40 mg) were injected into the hepatic artery by routine procedure, repeated every 4-6 weeks, and administered for 2-4 cycles. Treatment continues until the disease progresses, intolerable toxicity occurs, new anti-tumor treatment is started, informed consent is withdrawn, follow-up is lost, death occurs or treatment termination is required。

Screening will be performed between days - 21 and - 4. Informed consent was signed up to 4 weeks prior to the first day of cycle 1 before any screening procedure or evaluation was performed and the trial was fully explained to each subject.

Baseline evaluation results must be collected prior to the first trial drug administration (day 1 of cycle 1). Baseline assessments may be performed between days - 3 and - 1 or on day 1 of cycle 1. If performed within 3 days before the first day of cycle 1, the screening results can be used as baseline results.

The tumor imaging was evaluated every 8 weeks (± 7 days) since the first administration, and every 12 weeks (± 7 days) after 36 weeks. If there are clinical indications for disease progression, tumor evaluation is more frequent. In the event of disease progression, unacceptable toxicity, the subject's request to discontinue the trial or the subject's withdrawal of consent, the subject will discontinue the trial treatment.

When the trial treatment is stopped, the treatment visit shall be stopped within 7 days after the treatment is stopped in order to stop the treatment examination.

After the end of the treatment period (up to 2 years), subjects who can benefit from the study drug will continue to study the treatment of the drug until disease progression, intolerable adverse reactions, withdrawal of intensive care facility (ICF), other anti-tumor treatment, loss of follow-up, death or termination of the study.

After the occurrence of a clinical event, if it is judged by the investigators that it should be attributed to the progress of the disease and it is unlikely to recover even if the patient continues to receive treatment, it can be evaluated as clinical deterioration. It is up to the investigator to discuss and decide whether to continue or stop the treatment for the subject and record in the study file.

At the end of the study, subjects who are still under study treatment can continue to receive treatment through another extended study or other forms at the discretion of the investigator if they are stable or relieved in the efficacy evaluation and can tolerate the adverse reactions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04273100
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Recruiting
Phase Phase 2
Start date November 14, 2019
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04592029 - TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC Phase 1
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Not yet recruiting NCT03283956 - Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan N/A
Recruiting NCT03652467 - The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Phase 1
Recruiting NCT05031949 - Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma Phase 1
Completed NCT03533920 - Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma N/A
Recruiting NCT05992220 - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion Phase 2
Not yet recruiting NCT05057104 - Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
Completed NCT04599777 - TACE Combined With Sorafenib and Tislelizumab for Advanced HCC Phase 2
Completed NCT04599790 - TACE Combined With Lenvatinib and Sintilimab for Advanced HCC Phase 2
Recruiting NCT02967887 - Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC Phase 2
Recruiting NCT05608200 - Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC Phase 3
Recruiting NCT05608213 - Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC Phase 3
Completed NCT04926376 - Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC N/A
Recruiting NCT06133062 - Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma Phase 2
Completed NCT02989922 - A Study to Evaluate SHR-1210 in Subjects With Advanced HCC Phase 2
Completed NCT06408753 - Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
Withdrawn NCT03563170 - QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Phase 1/Phase 2
Recruiting NCT05390112 - Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
Recruiting NCT05713994 - Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma